Prolight have six families of patent applications relating to the Psyros single-molecule-counting technology. The first five families are currently in the national / regional phases in a range of territories worldwide. The sixth patent application entered the PCT (patent cooperation treaty) international phase in November 2025.
The first 2 patents were granted in Europe in Q2 2025 by the European Patent Office (EPO) and have now been validated in the following 17 European jurisdictions: France, Germany, Italy, Poland, Spain, United Kingdom, Austria, Belgium, Ireland, the Netherlands, Portugal, Sweden, Switzerland, Turkey, Denmark, Finland and Norway. This covers a population base of approximately 540 million people. A third patent was granted in Europe in December 2025 and has been validated in 11 European jurisdictions.
The first 2 patents were granted by the Japan Patent Office (JPO) in July 2025 and April 2026 respectively.
Notices of Allowance were received in July 2026 for the first patent in Korea (MOIP) and the second patent in the United States (USPTO) and these patents are expected to be granted shortly.
Family 1 patent (EP3987287 and JP7700055) protects the core technology and will remain in force until 2040.
Family 2 patent (EP4264266 and JP7867712) is an enhancement to the core technology and will remain in force until 2041.
Family 3 patent (EP4496995) uses 2 wavelengths to enhance signal generation and will remain in force until 2042.
A divisional application of family 1 patent (EP3987287) has also been filed (published as EP4549943) to seek greater scope for the core technology.
For MicroFlex, the patent portfolio consists of six registered patents (three in the US, two in the EU, and one in Sweden) and three patent applications that have advanced to the national phase and are now being pursued in various territories.
One of the patent applications pertains to how the sampling tube can be directly integrated into the test card. This enables a very simple workflow for all types of clinical environments. No specially trained personnel are needed to pipette and centrifuge the blood sample. MicroFlex thus creates the conditions to offer a fully automated platform for immunodiagnostics.
The most recently approved patent in the United States (May 2025) provides protection for the unique technical composition of the MicroFlex analytical device and reaction chamber. The patent is a testament to the technological height of MicroFlex.
The approved patent from October 2024 concerns a European patent based on a groundbreaking solution for separating plasma from whole blood in a liquid-based consumable. The separation produces high-quality plasma, requires minimal physical space, and is performed in a short amount of time, unlocking new potential business opportunities by integrating the technology into other liquid-based disposable systems.